Opportunity
Federal Register #2026-17274
DEA Notice: Curia New York Inc Application for Bulk Manufacturing of Controlled Substances
Buyer
Justice Department / Drug Enforcement Administration
Posted
August 25, 2026
Respond By
October 26, 2026
Identifier
2026-17274
NAICS
325412, 325199
The Drug Enforcement Administration (DEA) is announcing Curia New York Inc's application to become a registered bulk manufacturer of controlled substances. - Government Buyer: - Department of Justice (DOJ) - Drug Enforcement Administration (DEA) - OEM/Vendor: - Curia New York Inc - Products/Services Requested: - Authorization to manufacture bulk active pharmaceutical ingredients for the following controlled substances: - Gamma Hydroxybutyric Acid (drug code 2010, Schedule I) - Marihuana (drug code 7360, Schedule I) - Tetrahydrocannabinols (drug code 7370, Schedule I) - Amphetamine (drug code 1100, Schedule II) - Lisdexamfetamine (drug code 1205, Schedule II) - Methylphenidate (drug code 1724, Schedule II) - Pentobarbital (drug code 2270, Schedule II) - 4-Anilino-N-phenethyl-4-piperidine (ANPP, drug code 8333, Schedule II) - Unique/Notable Requirements: - Marihuana and Tetrahydrocannabinols will be manufactured as synthetic substances only - No other activities are authorized for these drug codes - DEA is soliciting public comments or objections to the registration - Written requests for a hearing may be submitted - No specific purchase quantities or part numbers provided; focus is on regulatory registration, not procurement of physical products.
Description
Curia New York Inc has applied to be registered as a bulk manufacturer of basic classes of controlled substances. The company plans to manufacture these substances as bulk active pharmaceutical ingredients for use in product development and distribution to customers. The application includes controlled substances such as Gamma Hydroxybutyric Acid, Marihuana, Tetrahydrocannabinols, Amphetamine, Lisdexamfetamine, Methylphenidate, Pentobarbital, and 4-Anilino-N-phenethyl-4-piperidine (ANPP). Comments or objections to the proposed registration must be submitted by October 26, 2026, and a written request for a hearing can also be filed by that date.